彝药恒古骨伤愈合剂的药理作用和临床应用
|
摘要
目的对恒古骨伤愈合剂镇痛抗炎、促进骨分化等药理作用和临床应用情况进行综述,为进一步研究和临床用药选择提供依据。方法通过大量查阅恒古骨伤愈合剂相关书籍与资料,总结归纳恒古骨伤愈合剂镇痛抗炎、促进骨分化等药理作用和临床应用。结果恒古骨伤愈合剂是以传统中药材黄芪、人参、红花、三七、杜仲、鳖甲、陈皮、钻地风、洋金花等组成的复方制剂,具有活血益气、补肝肾、消肿止痛、促进骨折愈合等功效。近年来动物实验及临床试验均证实其对骨质疏松、骨折、股骨头坏死、腰间盘突出症等具有显著疗效,临床应用广泛。恒古骨伤愈合剂主要不良事件有消化系统损伤、服药过量导致意识不清等,在停药或对症治疗后均能得到控制。结论恒古骨伤愈合剂具有多种药理作用,经临床应用证实,其疗效较好。
OBJECTIVE To review the pharmacological action and clinical application of Osteoking, such as analgesic and anti-inflammatory, and promoting bone differentiation, etc. Provide basis for further research and clinical selection. METHODS Through a large number of books and materials on Osteoking were reviewed to summarize its analgesic and anti-inflammatory mechanisms and so on. Summed up the Osteoking pharmacological action and clinical application. RESULTS Osteoking was a Chinese traditional medicine compound, which was composed of astragalus, ginseng, safflower, panax notoginseng, eucommia ulmoides, turtle shelland, tangerine peel, schizophragma, flos daturae, and other drugs. Animal experiments and clinical research confirmed that Osteoking exerted benefical effects on osteoporosis, fracture, femoral head necrosis, lumbar disc herniation and so on. It was widely used in clinical practice. Adverse drug events of Osteoking included digestive system damage, any loss of mental faculties right, etc. However, these adverse drug reactions would be controlled after drug withdrawal or symptomatic treatment. CONCLUSION Osteoking has a variety of pharmacological effects. After years of clinical application, its clinical efficacy has been confirmed.
OBJECTIVE To review the pharmacological action and clinical application of Osteoking, such as analgesic and anti-inflammatory, and promoting bone differentiation, etc. Provide basis for further research and clinical selection. METHODS Through a large number of books and materials on Osteoking were reviewed to summarize its analgesic and anti-inflammatory mechanisms and so on. Summed up the Osteoking pharmacological action and clinical application. RESULTS Osteoking was a Chinese traditional medicine compound, which was composed of astragalus, ginseng, safflower, panax notoginseng, eucommia ulmoides, turtle shelland, tangerine peel, schizophragma, flos daturae, and other drugs. Animal experiments and clinical research confirmed that Osteoking exerted benefical effects on osteoporosis, fracture, femoral head necrosis, lumbar disc herniation and so on. It was widely used in clinical practice. Adverse drug events of Osteoking included digestive system damage, any loss of mental faculties right, etc. However, these adverse drug reactions would be controlled after drug withdrawal or symptomatic treatment. CONCLUSION Osteoking has a variety of pharmacological effects. After years of clinical application, its clinical efficacy has been confirmed.
引文
[1]WAN Y X,XU L L,ZHUO N Q,et al.Research advance on the effect of autophagy on bone metabolism in osteoporosis[J].Chin J Osteoporosis(中国骨质疏松杂志),2018,24(4):552-556.
[2]DAI L F,WU H Y,YU S,et al.Effects of OsteoKing on osteoporotic rabbits[J].Mol Med Rep,2015,12(1):1066-1074.
[3]SUN Y,CHEN R,WANG X Q,et al.The effects of Osteoking on ovariectomized female rat model of osteoporosis[J].Chin JOsteoporosis(中国骨质疏松杂志),2016,22(12):1513-1515.
[4]ZHANG H J,WANG X Q,SUN Y,et al.Initially isolation and bone-forming activity evaluation of Osteoking[J].Chin JTradit Chin Med Pharm(中华中医药杂志),2018,33(4):1512-1515.
[5]LI Y,TONG J,ZHOU Y J,et al.Research progress on anti-osteoporotic active ingredients and pharmacological action mechanism of traditional Chinese kidney-tonifying and bone-strengthening drugs[J].China J Chin Mater Med(中国中药杂志),2015,40(6):1038-1043.
[6]JIANG Y,XU Y J.BMP-TGFβsignal pathway[J].Chin JOsteoporosis(中国骨质疏松杂志),2016,22(11):1485-1487.
[7]郑红,李进涛,赵宏斌,等.恒古骨伤愈合剂促进骨细胞增殖缓解骨质疏松症树鼩的分子机制[J].中药药理与临床,2017,33(4):133-136.
[8]ZHAO H B,HU M,LIANG H S,et al.Experiment study on Osteoking in promoting gene expressing of core binding factor alpha 1 in necrotic femoral head of rabbits[J].Chin J Integr Tradit West Med(中国中西医结合杂志),2006,26(11):1003-1006.
[9]XIAO M,SANG H L,ZHOU A F,et al.Effects of horror injuring pregnant rats on filial rats long bone early development[J].Liaoning J Tradit Chin Med(辽宁中医杂志),2017,44(8):1744-1747.
[10]POON B,KHA T,TRAN S,et al.Bone morphogenetic protein-2 and bone therapy:successes and pitfalls[J].J Pharm Pharmacol,2016,68(2):139-147.
[11]胡敏.恒古骨伤愈合剂对实验性骨质疏松症的治疗作用及其机制研究[D].贵州:贵阳医学院,2013.
[12]刘焕,孙磊,刘华,等.骨关节炎患者血清中DKK-1和MMP-13水平的相关研究[J].陕西医学杂志,2018,47(4):414-416.
[13]ZHANG B L,LIU W L.Research progress on the wnt inhibitor DKK-1 in steroid induced avascular necrosis of the femorl head[J].J Inner Mongolia Med Univ(内蒙古医科大学学报),2016,38(4):366-369.
[14]WANG S B,ZHAO H B,HU M,et al.Effect of Osteoking on bone mineral density and Dickkopf-1 protein levels in rabbits with osteoporotic fracture[J].Chin J Integr Tradit West Med(中国中西医结合杂志),2015,35(8):1000-1003.
[15]QIAN S X,SHEN Y F,ZHANG X L,et al.Effect of type 2diabetes mellitus on the platelet derived endothelial cell growth factor and vascular endothelial growth factor in patients with cerebral infarction[J].Chin J Clin Pharm(中国临床药理学杂志),2018,34(7):783-785.
[16]CHEN Z Q,HONG Y Q,CHEN Z,et al.Effect of Danshen injection on PLON fracture healing as well as BMP-7,TGF-β1and bFGF expression[J].J Hainan Med Univ(海南医学院学报),2016,22(22):94-97.
[17]WU J F,ZHAN R X.Impact of henggu gushang heji on rabbit fracture healing[J].Chin J Clin Rat Drug Use(临床合理用药杂志),2017,10(27):13-14.
[18]ZHAO H B,HU M,WANG W Q,et al.Effects of the VEGFgene expressions of osteoking in the treatment of femoral head necrosis[J].Chin J Orthopaedics Traumatol(中国骨伤),2007,20(11):757-759.
[19]WU C,TANG W,ZHAO H B,et al.Effect of Osteoking on blood physiological parameters and organ indexes in female tree shrews with osteoporotic fracture[J].Chin J Comparat Med(中国比较医学杂志),2017,27(11):1-5.
[20]CHEN Z N,ZHOU Z,WANG W M,et al.Experimental study of Osteoking on bone reconstruction after lumbar laminectomy and bone grains replantation surgery[J].Chin Med Herald(中国医药导报),2015,12(35):12-15.
[21]王振,张晓刚,宋敏,等.换气按压法、后仰旋转法配合消定膏治疗腰椎间关节紊乱型急性腰扭伤疗效观察[J].辽宁中医杂志,2017,44(4):761-763.
[22]周兆文,普有登,袁晓峰,等.恒古骨伤愈合剂治疗急性腰扭伤的疗效观察[J].云南医药,2012,33(5):435-436.
[23]YU X F,PENG W X,CHEN K Y,et al.Metabonomic study on the mechanism of steroid-induced avasular necrosis of femoral head with Gushiling Capsule[J].China J Tradit Chin Med Pharm(中华中医药杂志),2014,29(6):1805-1808.
[24]蒙锡波,邓丽丽.恒古骨伤愈合剂联合活血补肾汤治疗激素性股骨头坏死疗效及对骨密度的影响[J].现代中西医结合杂志,2018,27(1):82-85.
[25]胡敏,赵宏斌,王兵,等.恒古骨伤愈合剂促进胫骨下段骨折术后愈合临床观察[J].中国中西医结合杂志,2005,25(2):160-161.
[26]张正彪,王平,罗洪磊,等.手术结合中药治疗桡骨远端粉碎性骨折及关节内骨折疗效观察[J].亚太传统医药,2013,9(6):115-116.
[27]SHEN L.A prospective clinical study for Osteoking treating traumatic rib fractures[D].Kunming:Kunming Medical University(昆明医科大学),2015.
[28]赵宏斌,胡敏,邱智兴,等.恒古骨伤愈合剂治疗腰椎间盘突出症37例长期疗效观察[J].云南中医中药杂志,2006,27(5):3-4.
[29]HU M,WANG B,ZHAO H B,et al.Prophylactic medication of Osteoking for the incidence of femoral head necrosis and the degree of weight loading-induced hip ache half a year after the operation of femoral neck fracture[J].Chin J Clin Rehabilit(中国临床康复),2005,9(14):158-159.
[30]于海峰,黄青,张宁.恒古骨伤愈合剂治疗Ⅱ期股骨头缺血性坏死60例临床观察[C]//跨世纪骨伤杰出人才科技成果荟萃.2004:941-942.
[31]洪亮亮,黄清秀,张涛.恒古骨伤愈合剂口服致腹痛腹泻1例[J].中国药业,2015,24(4):95.
[32]张荣博,章水晶,徐彬.恒古骨伤愈合剂过量致意识障碍1例[J].贵阳中医学院学报,2015,37(1):71-72.
[33]ZHENG Z Q,LUO J Y.Pharmaceutical care for a case of drug-induced liver injury by clinical pharmacists[J].Chin JPharmacoepidemiol(药物流行病学杂志),2016,25(10):650-655.
[34]李幸苗,鲁洪辰,应盈,等.基于我院2012-2015年住院部中成药使用情况探讨临床合理用药[J].中成药,2017,39(9):1989-1992.
[35]倪观锋,苏亚军.我院门诊骨伤科口服中成药应用分析[J].海峡药学,2013,25(4):259-260.
[36]洪莹,毛亚俊,王珍华.2009至2010年我院病区口服中成药应用分析[J].中国药业,2012,21(8):75-76.
[2]DAI L F,WU H Y,YU S,et al.Effects of OsteoKing on osteoporotic rabbits[J].Mol Med Rep,2015,12(1):1066-1074.
[3]SUN Y,CHEN R,WANG X Q,et al.The effects of Osteoking on ovariectomized female rat model of osteoporosis[J].Chin JOsteoporosis(中国骨质疏松杂志),2016,22(12):1513-1515.
[4]ZHANG H J,WANG X Q,SUN Y,et al.Initially isolation and bone-forming activity evaluation of Osteoking[J].Chin JTradit Chin Med Pharm(中华中医药杂志),2018,33(4):1512-1515.
[5]LI Y,TONG J,ZHOU Y J,et al.Research progress on anti-osteoporotic active ingredients and pharmacological action mechanism of traditional Chinese kidney-tonifying and bone-strengthening drugs[J].China J Chin Mater Med(中国中药杂志),2015,40(6):1038-1043.
[6]JIANG Y,XU Y J.BMP-TGFβsignal pathway[J].Chin JOsteoporosis(中国骨质疏松杂志),2016,22(11):1485-1487.
[7]郑红,李进涛,赵宏斌,等.恒古骨伤愈合剂促进骨细胞增殖缓解骨质疏松症树鼩的分子机制[J].中药药理与临床,2017,33(4):133-136.
[8]ZHAO H B,HU M,LIANG H S,et al.Experiment study on Osteoking in promoting gene expressing of core binding factor alpha 1 in necrotic femoral head of rabbits[J].Chin J Integr Tradit West Med(中国中西医结合杂志),2006,26(11):1003-1006.
[9]XIAO M,SANG H L,ZHOU A F,et al.Effects of horror injuring pregnant rats on filial rats long bone early development[J].Liaoning J Tradit Chin Med(辽宁中医杂志),2017,44(8):1744-1747.
[10]POON B,KHA T,TRAN S,et al.Bone morphogenetic protein-2 and bone therapy:successes and pitfalls[J].J Pharm Pharmacol,2016,68(2):139-147.
[11]胡敏.恒古骨伤愈合剂对实验性骨质疏松症的治疗作用及其机制研究[D].贵州:贵阳医学院,2013.
[12]刘焕,孙磊,刘华,等.骨关节炎患者血清中DKK-1和MMP-13水平的相关研究[J].陕西医学杂志,2018,47(4):414-416.
[13]ZHANG B L,LIU W L.Research progress on the wnt inhibitor DKK-1 in steroid induced avascular necrosis of the femorl head[J].J Inner Mongolia Med Univ(内蒙古医科大学学报),2016,38(4):366-369.
[14]WANG S B,ZHAO H B,HU M,et al.Effect of Osteoking on bone mineral density and Dickkopf-1 protein levels in rabbits with osteoporotic fracture[J].Chin J Integr Tradit West Med(中国中西医结合杂志),2015,35(8):1000-1003.
[15]QIAN S X,SHEN Y F,ZHANG X L,et al.Effect of type 2diabetes mellitus on the platelet derived endothelial cell growth factor and vascular endothelial growth factor in patients with cerebral infarction[J].Chin J Clin Pharm(中国临床药理学杂志),2018,34(7):783-785.
[16]CHEN Z Q,HONG Y Q,CHEN Z,et al.Effect of Danshen injection on PLON fracture healing as well as BMP-7,TGF-β1and bFGF expression[J].J Hainan Med Univ(海南医学院学报),2016,22(22):94-97.
[17]WU J F,ZHAN R X.Impact of henggu gushang heji on rabbit fracture healing[J].Chin J Clin Rat Drug Use(临床合理用药杂志),2017,10(27):13-14.
[18]ZHAO H B,HU M,WANG W Q,et al.Effects of the VEGFgene expressions of osteoking in the treatment of femoral head necrosis[J].Chin J Orthopaedics Traumatol(中国骨伤),2007,20(11):757-759.
[19]WU C,TANG W,ZHAO H B,et al.Effect of Osteoking on blood physiological parameters and organ indexes in female tree shrews with osteoporotic fracture[J].Chin J Comparat Med(中国比较医学杂志),2017,27(11):1-5.
[20]CHEN Z N,ZHOU Z,WANG W M,et al.Experimental study of Osteoking on bone reconstruction after lumbar laminectomy and bone grains replantation surgery[J].Chin Med Herald(中国医药导报),2015,12(35):12-15.
[21]王振,张晓刚,宋敏,等.换气按压法、后仰旋转法配合消定膏治疗腰椎间关节紊乱型急性腰扭伤疗效观察[J].辽宁中医杂志,2017,44(4):761-763.
[22]周兆文,普有登,袁晓峰,等.恒古骨伤愈合剂治疗急性腰扭伤的疗效观察[J].云南医药,2012,33(5):435-436.
[23]YU X F,PENG W X,CHEN K Y,et al.Metabonomic study on the mechanism of steroid-induced avasular necrosis of femoral head with Gushiling Capsule[J].China J Tradit Chin Med Pharm(中华中医药杂志),2014,29(6):1805-1808.
[24]蒙锡波,邓丽丽.恒古骨伤愈合剂联合活血补肾汤治疗激素性股骨头坏死疗效及对骨密度的影响[J].现代中西医结合杂志,2018,27(1):82-85.
[25]胡敏,赵宏斌,王兵,等.恒古骨伤愈合剂促进胫骨下段骨折术后愈合临床观察[J].中国中西医结合杂志,2005,25(2):160-161.
[26]张正彪,王平,罗洪磊,等.手术结合中药治疗桡骨远端粉碎性骨折及关节内骨折疗效观察[J].亚太传统医药,2013,9(6):115-116.
[27]SHEN L.A prospective clinical study for Osteoking treating traumatic rib fractures[D].Kunming:Kunming Medical University(昆明医科大学),2015.
[28]赵宏斌,胡敏,邱智兴,等.恒古骨伤愈合剂治疗腰椎间盘突出症37例长期疗效观察[J].云南中医中药杂志,2006,27(5):3-4.
[29]HU M,WANG B,ZHAO H B,et al.Prophylactic medication of Osteoking for the incidence of femoral head necrosis and the degree of weight loading-induced hip ache half a year after the operation of femoral neck fracture[J].Chin J Clin Rehabilit(中国临床康复),2005,9(14):158-159.
[30]于海峰,黄青,张宁.恒古骨伤愈合剂治疗Ⅱ期股骨头缺血性坏死60例临床观察[C]//跨世纪骨伤杰出人才科技成果荟萃.2004:941-942.
[31]洪亮亮,黄清秀,张涛.恒古骨伤愈合剂口服致腹痛腹泻1例[J].中国药业,2015,24(4):95.
[32]张荣博,章水晶,徐彬.恒古骨伤愈合剂过量致意识障碍1例[J].贵阳中医学院学报,2015,37(1):71-72.
[33]ZHENG Z Q,LUO J Y.Pharmaceutical care for a case of drug-induced liver injury by clinical pharmacists[J].Chin JPharmacoepidemiol(药物流行病学杂志),2016,25(10):650-655.
[34]李幸苗,鲁洪辰,应盈,等.基于我院2012-2015年住院部中成药使用情况探讨临床合理用药[J].中成药,2017,39(9):1989-1992.
[35]倪观锋,苏亚军.我院门诊骨伤科口服中成药应用分析[J].海峡药学,2013,25(4):259-260.
[36]洪莹,毛亚俊,王珍华.2009至2010年我院病区口服中成药应用分析[J].中国药业,2012,21(8):75-76.